FDA approves ThyroKare for hypothyroidism in dogs

The FDA’s Center for Veterinary Medicine has approved ThyroKare (levothyroxine sodium tablets) from Neogen to treat hypothyroidism in dogs.

According to the agency, this is the second levothyroxine sodium product approved for replacement therapy for diminished thyroid function in dogs.

Hypothyroidism occurs when the thyroid gland doesn’t produce and secrete enough thyroid hormones, which are important in metabolism and affect the function of many parts of the body. The condition is a common hormone imbalance in dogs and is usually caused by inflammation or shrinkage of the thyroid gland. This progressive destruction of the gland leads to diminished thyroid function and insufficient levels of thyroid hormones.

The condition is typically seen in middle-aged to older dogs and occurs more commonly in medium to large breed dogs.

ThyroKare is available by prescription only since professional expertise is required to diagnose hypothyroidism and to monitor the safe use of the product, including treatment of any adverse reactions.

The drug is available in nine strengths of color-coded tablets from 0.1 to 1 milligram, in bottles of 180 and 1,000 tablet counts.